background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

OTHER
SOLID TUMORS

*Developed in collaboration with Molecular Partners.1

DARPin, designed ankyrin repeat proteins; FAP, fibroblast activation protein; HCC, hepatocellular carcinoma; IL-21R, interleukin 21 receptor; KIF18A, kinase-like protein 18A; KRAS, Kirsten rat sarcoma; MetMel, metastatic melanoma; MOA, mechanism of action; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1.

References
1. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 7/27/2021. 2. Govindan R, et al. Presented at: American Society of Clinical Oncology; Virtual Meeting; June 4–8, 2021. 3. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03600883. Accessed 8/27/21. 4. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04185883. Accessed 8/27/21. 5. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04303780. Accessed 7/29/21. 6. Choi AH, et al. Biomedicines. 2016;4:18. doi:10.3390/biomedicines400018. 7. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02263508. Accessed 7/29/21. 8. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04068181. Accessed 7/29/21. 9. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02910557. Accessed 7/29/21. 10. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02509507. Accessed 7/29/21. 11. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02756845. Accessed 8/27/21. 12. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03256344. Accessed 7/29/21.
Molecule
Modality1
Target1
Areas of Investigation1
AMG 256
Target1
Areas of Investigation1
Molecule
Modality1
Target1
Areas of Investigation1
AMG 404
Target1
Areas of Investigation1
Molecule
Modality1
Target1
Areas of Investigation
AMG 506*
Molecule
Modality1
Target2
Areas of Investigation1
AMG 650
Target2
Areas of Investigation1
Molecule
Modality1
Target1
Areas of Investigation3-5
Sotorasib
Target1
Areas of Investigation3-5
Molecule
Modality6
Target6
Areas of Investigation7-12
Talimogene laherparepvec
Modality6
Areas of Investigation7-12

*Developed in collaboration with Molecular Partners.1

DARPin, designed ankyrin repeat proteins; FAP, fibroblast activation protein; HCC, hepatocellular carcinoma; IL-21R, interleukin 21 receptor; KIF18A, kinase-like protein 18A; KRAS, Kirsten rat sarcoma; MetMel, metastatic melanoma; MOA, mechanism of action; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1.

References
1. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 7/27/2021. 2. Govindan R, et al. Presented at: American Society of Clinical Oncology; Virtual Meeting; June 4–8, 2021. 3. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03600883. Accessed 8/27/21. 4. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04185883. Accessed 8/27/21. 5. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04303780. Accessed 7/29/21. 6. Choi AH, et al. Biomedicines. 2016;4:18. doi:10.3390/biomedicines400018. 7. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02263508. Accessed 7/29/21. 8. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04068181. Accessed 7/29/21. 9. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02910557. Accessed 7/29/21. 10. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02509507. Accessed 7/29/21. 11. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02756845. Accessed 8/27/21. 12. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03256344. Accessed 7/29/21.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.